Contents

Search

nabumetone (Relafen)

Tradename: Relafen. Indications: - osteoarthritis - rheumatoid arthritis - ankylosing spondylitis [6] - gout [6] Dose: 1-2 g PO QD or divided BID. Tabs: 500, 750 mg. Monitor: - liver function tests periodically [5] Adverse effects: -> may be less nephrotoxic than other NSAIDs because it is metabolized to inactive metabolites before excretion into the urine [3] Mechanism of action: - inhibits cyclooxygenase, some selectivity for COX-2 [4]

Interactions

drug interactions drug adverse effects of NSAIDs monitor with non steroidal anti-inflammatory agents (NSIADs)

General

non-steroidal anti-inflammatory agent (NSAID)

Properties

INHIBITS: cyclooxygenase MISC-INFO: elimination route LIVER 1/2life 24 HOURS pregnancy-category C safety in lactation -

Database Correlations

PUBCHEM cid=4409

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Kaiser Permanente Northern California, Drug update, 9/2000
  3. Prescriber's Letter 10(5):29 2003
  4. Prescriber's Letter 12(3): 2005
  5. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: 260704 (subscription needed) http://www.prescribersletter.com
  6. Deprecated Reference